Background {#Sec1}
==========

Obesity, type 2 diabetes mellitus (T2DM), and human immunodeficiency virus (HIV) are prominent global health issues. With the advent of highly active antiretroviral treatment (HAART) and improved mortality rates, people with HIV infection increasingly present with obesity and related metabolic consequences \[[@CR1]\]. Bariatric procedures, including adjustable gastric banding (AGB), sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB), are effective therapies for morbid obesity with high rates of T2DM resolution \[[@CR2]\]. Until recently, however, bariatric surgery in the HIV-positive population remained controversial \[[@CR3]\].

The first report of a patient with HIV infection undergoing bariatric surgery was in 2005 \[[@CR4]\], and, subsequently, a small number of studies, including within our own unit, have reported outcomes \[[@CR5]\]. Bariatric surgery is now considered a safe and effective treatment for people with morbid obesity who are also infected with HIV \[[@CR6]\]. Notably, to date, there are limited descriptions of T2DM outcomes in such individuals. Given the increasing prevalence of this combination of conditions, we present a case series to advance this discussion.

Cases presentation {#Sec2}
==================

Methods of case collection {#Sec3}
--------------------------

We studied 120 patients with T2DM who underwent bariatric surgery between 2010 and 2017 at Chelsea and Westminster Hospital, London. The patients groups were: AGB (*n* = 62) and SG (*n* = 58). Three patients known to be HIV antibody positive form the basis of this series. Selection for bariatric surgery was consistent with National Institute for Health and Care Excellence (NICE) guidelines with procedural type co-decided by the patient and the multidisciplinary team (MDT). Procedural descriptions are provided elsewhere \[[@CR7]\]. Utilizing hospital pathology and electronic record systems, information was collected on: demographics; anthropometrics; weight history; surgical details; perioperative diabetes status; perioperative HIV status, and major outcomes.

Case 1 {#Sec4}
------

Case 1 is a 58-year-old Caucasian male with a history of HIV infection (2002), T2DM (2008), and obesity. His comorbidities included hypertension, dyslipidemia, and obstructive sleep apnea. (Table [1](#Tab1){ref-type="table"}). Preoperatively, he was prescribed metformin 500 mg twice a day and glycated hemoglobin (HbA1c) was 40 mmol/mol. His baseline body mass index (BMI) was 47 kg/m^2^, with a weight of 162.9 kg. Multiple attempts at weight loss, including commercial diets and orlistat, had been unsuccessful. HIV prescriptions included one tablet daily of Atripla (efavirenz/emtricitabine/tenofovir). His preoperative CD4 count was 800 cells/μL and viral load was undetectable. Following assessment by the bariatric MDT, he was found to meet criteria for surgery.Table 1Preoperative assessment for the bariatric surgery on admissionCase 1Case 2Case 3Past medical historyHypertension, dyslipidemia, T2DM, obstructive sleep apnea, obesity, gout, Burkitt's lymphoma, HIV, CKD stage 2, hydrocele repair, tonsillectomyObesity, T2DM, obstructive sleep apnea, depression, HIV, fatty liver disease, tonsillectomyObesity, T2DM, asthma, dyslipidemia, obstructive sleep apnea, urinary incontinence, peripheral neuropathy, knee osteoarthritis, depression, vitamin D deficiency.Drug historyAllergic to co-trimoxazole.\
Metformin 500 mg twice a day\
Losartan 100 mg once a day\
Allopurinol 200 mg once a day\
Atorvastatin 10 mg once a day\
Indapamide 1.5 mg once a dayNo known drug allergy.\
Mirtazapine 30 mg once a day\
Metformin 500 mg once a dayNo known drug allergy.\
Ranitidine 300 mg once a day\
Atorvastatin 10 mg once a day\
Metformin 1 g three times a day\
Dapagliflozin 10 mg once a day\
Exenatide 20 mcg once a day\
Detemir 70 units twice a day HIV medicationsAtripla (efavirenz/emtricitabine/tenofovir) 1 tablet once a dayAtripla (efavirenz/emtricitabine/tenofovir) 1 tablet once a dayTruvada (emtricitabine/tenofovir) 245/200 mg once a day\
Darunavir 800 mg once a day\
Ritonavir 100 mg once a dayFamily historyFather -- aortic aneurysm\
Mother -- Alzheimer'sNilNilSocial history Tobacco smokingNilOccasionalNil Alcohol40 units/monthOccasionalNil EmploymentComputer programmerUnemployedUnemployed IndependenceLives with family, independent of daily activitiesLives with friends, independent of daily activitiesLives with daughter, wheelchair bound most of the timeObservationsHR -- 70HR -- 100HR -- 83RR -- 16RR -- 16RR -- 18Sats -- 99%Sats -- 95%Sats -- 95%BP -- 128/72BP -- 136/90BP -- 145/83T -- 36.4 °CT -- 36.1 °CT -- 36.7 °CPhysical examinationsMild right knee joint painMild bilateral joint pain and low back pain.\
Fungal infection right axillaMild bilateral joint pain and low back pain.Neurology examinationsNADNADNumbness below the knee bilaterally.\
Urinary incontinence*BP* blood pressure, *CKD* chronic kidney disease, *HIV* human immunodeficiency virus, *HR* heart rate, *NAD* no abnormality detected, *RR* respiration rate, *Sats* oxygen saturation, *T* temperature, *T2DM* type 2 diabetes mellitus

In 2012 he underwent laparoscopic AGB surgery and had an uncomplicated postoperative course. Preoperative and postoperative clinical parameters are presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"} with sustained weight loss reported. As per local guidelines, this patient continued to receive metformin 500 mg twice a day postoperatively to optimize insulin sensitivity. Six months postoperatively, HbA1c was 35 mmol/mol, and there was no evidence of diabetes-related complications. His HIV infection status was not affected by surgery, and he continued to receive Atripla (efavirenz/emtricitabine/tenofovir). His CD4 count was unchanged at each postoperative visit, with undetectable viral load throughout. He continues to be on antiretroviral and antidiabetic medications as well (metformin 500 mg twice a day) and reports sustained weight loss.Table 2Preoperative and final postoperative clinical parameters for Cases 1--3Case 1Case 2Case 3preoperativelyPostoperatively^4^preoperativelyPostoperatively^4^preoperativelyPostoperatively^4^BMI (kg/m^2^)4437.848.137.947.941.1Weight (kg)152.1132.1142.2112.0118.0101.2% TWL^1^6.6%18.9%5.1%25.2%−0.2%14.1%% EWL^2^14.3%40.8%10.0%49.8%−0.4%29.5%HbA1c (mmol/mol)^3^4133353412890Diabetes medicationsMetformin 500 mg twice a dayMetformin 500 mg twice a dayMetformin 500 mg once a dayNilMetformin 1 g three times a day\
Dapagliflozin 10 mg once a day\
Exenatide 20 mcg once a day\
Detemir 70 units twice a dayMetformin 1 g twice a day\
Dapagliflozin 10 mg once a day\
Humulin M3 (human insulin, mixture 3)\
(22 units OM, 16 units ON)CD4 count (cells/μL)750845929718440372Viral load (cp/ml)\< 40\< 40\< 40\< 20\< 40\< 20HIV medicationsAtripla 1 Tab once a dayAtripla (efavirenz/emtricitabine/tenofovir) 1 Tab once a dayAtripla (efavirenz/emtricitabine/tenofovir) 1 Tab once a dayTruvada (emtricitabine/tenofovir) 245/200 mg once a day\
Raltegravir 400 mg twice a dayTruvada (emtricitabine/tenofovir) 245/200 mg once a day\
Darunavir 800 mg once a day\
Ritonavir 100 mg once a dayTruvada (emtricitabine/tenofovir) 245/200 mg once a day\
Rezolsta (darunavir/cobicistat) 800/150 mg once a dayComplicationsVitamin D deficiencyNilStricture*BMI* body mass index, *EWL* excessive weight loss,*HbA1c* glycated hemoglobin, *HIV* human immunodeficiency virus, *Tab* tablet, *TWL* total weight loss, *OM* in the morning, *ON* at night. ^1^ % *TWL*: percentage of total weight loss, ^2^ % *EWL*: percentage of excess weight loss, calculated by dividing weight changes from baseline by excess body weight. The latter value was obtained by subtracting the ideal body weight as that equivalent to a body mass index of 25 kg/m2 from the actual baseline weight, ^3^ normal range of glycated haemoglobin is 20--41 mmol/mol, ^4^ last follow-up (\> 3 years in all cases)Table 3Results of routine laboratory tests pre-bariatric operation and post-bariatric operationCase 1Case 2Case 3Preoperation\*Postoperation\^Preoperation\*Postoperation\^Preoperation\*Postoperation\^FBC Hb (g/L)129156143165122119 WCC (×10^9^/L)4.95.98.17.34.33.2 PLT (×10^9^/L)149204186243270182 CRP (mg/L)285112221U&Es Na (mmol/L)138142138139137144 K (mmol/L)3.83.64.34.64.14.3 Urea (mmol/L)4.66.52.25.44.07.2 Cr (mmol/L)9413967548065 eGFR (ml/minute/1.73m^2^)7347\> 90\> 9067\> 90LFTs Bili (μmol/l)1069964 ALP (IU/L)303445301019 ALT (IU/L)5965809510966 ALB (g/L)364035412833Urine analysis Specific gravity1.0301.0301.0151.0201.0301.010 pH5.55.06.05.55.56.0 Protein (mg/L)Negative+NegativeNegative++ Glucose (mmol/L)NegativeNegativeNegativeNegative++ Urine cultureNegativeNegativeNegativeNegativeNegativeNegative Fecal cultureN/AN/AN/AN/AN/AN/A Blood cultureN/AN/AN/AN/AN/AN/A*ALB* albumin, *ALP* alkaline phosphatase, *ALT* alanine aminotransferase, *Bili* bilirubin, *Cr* creatinine, *CRP* C-reactive protein, *eGFR* estimated glomerular filtration rate, *FBC* full blood count, *Hb* hemoglobin, *K* potassium, *LFTs* liver function tests, *Na* sodium, *N/A* not applicable, *PLT* platelet, *U&Es* urea and electrolytes, *WCC* white cell count\*on admission to receive bariatric surgery, \^last follow-up (\> 3 years postoperation for all cases)Fig. 1Line graph illustrating changes in clinical parameters for Cases 1--3. **a**, **b** Weight status. **c** Glycemic control. **d** Human immunodeficiency virus status. BMI body mass index, HbA1c glycated hemoglobin

Case 2 {#Sec5}
------

Case 2 is a 33-year-old Caucasian male who was positive for HIV (2011) with a background of T2DM, obesity, depression, and fatty liver disease (Table [1](#Tab1){ref-type="table"}). His baseline BMI was 50.7 kg/m^2^ with a weight of 149.8 kg. Following 2 years of orlistat therapy and lifestyle intervention, his BMI decreased modestly to 48.1 kg/m^2^. Preoperatively, T2DM was controlled with metformin 500 mg once a day and his HbA1c was 35 mmol/mol. Following 2 years of HAART for which he received Atripla (efavirenz/emtricitabine/tenofovir) 1 tablet once a day, his CD4 count increased to 929 cells/μL from 552 cells/μL at diagnosis. Viral load was undetectable. Further preoperative and postoperative parameters are presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}.

A laparoscopic SG was performed in 2013. He reported no complications at postoperative follow-up. T2DM was diet controlled following surgery and his HbA1c remained stable (33 mmol/mol mean). Therefore, complete diabetes remission was achieved according to American Diabetes Association (ADA) criteria \[[@CR8]\]. Postoperatively, his viral load remained undetectable with a mean CD4 count of 735 cells/μL. Following clinical trial recruitment, antiretroviral medication was adjusted in an attempt to better stabilize mood. Depressive symptoms improved and HIV status remained stable.

Case 3 {#Sec6}
------

Case 3 is a 48-year-old Caucasian female with a history of obesity, HIV disease (2003), and poorly controlled T2DM with peripheral neuropathy (2003) (Table [1](#Tab1){ref-type="table"}). Her baseline BMI was 47.8 kg/m^2^ and multiple attempts at weight loss had been unsuccessful. Her preoperative HIV status was well controlled (CD4 count 440 cells/μL, undetectable viral load) with Truvada (emtricitabine/tenofovir), darunavir, and ritonavir. Unfortunately, despite various treatments of sodium-glucose co-transporter-2 (SGLT-2) inhibitor, high-dose insulin sensitizer, glucagon-like peptide-1 (GLP-1) agonist, and high-dose basal insulin, her HbA1c remained elevated at 128 mmol/mol. Extensive discussions were undertaken with the patient and the MDT. Despite lack of glycemic optimization, benefits were deemed to outweigh risks and so SG was scheduled.

Preoperative and postoperative clinical parameters are presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. Her T2DM status improved following surgery: HbA1c dropped to 90 mmol/mol 2 years postoperatively (accompanying fasting glucose of 12 mmol/L). Unsurprisingly, given T2DM duration, preceding control, and preoperative insulin requirements, diabetes remission was not achieved in this case. Following surgery, however, she benefits from a reduced pill burden and markedly reduced daily insulin requirements (38 versus 140 units preoperatively). Anti-retroviral medications were switched to Truvada (emtricitabine/tenofovir) and Rezolsta (darunavir/cobicistat) and her HIV status remained stable (CD4 count 400 cells/μL, undetectable viral load). An esophageal stricture which developed 2 years postoperatively responded to a dilatation procedure. No further complications have occurred.

Discussion {#Sec7}
==========

Here we present three differing cases which add to the literature supporting bariatric surgery as a safe treatment modality in individuals who are HIV positive. Our cases series is novel as we have compared the effects of bariatric surgery on weight reduction and glycemic control in patients with HIV infection as well as patients without HIV infection.

T2DM prevalence and complication rates in the HIV-infected population (23--40%) are noticeably higher than the general population \[[@CR9]\]. Traditional risk factors as well as HIV-specific factors including anti-retrovirals and lipodystrophy syndrome contribute to the pathogenesis \[[@CR9]\]. A strong body of evidence supports the use of bariatric surgery as a treatment modality for T2DM in the context of obesity \[[@CR10]\] with sustained remission of T2DM described \[[@CR7]\]. Also reported are improvements in cardiovascular risk profile, obesity-related complications, and all-cause mortality \[[@CR2], [@CR7]\]. Despite this, bariatric surgery remains an underutilized tool and data are limited for the HIV-infected population. Although reports \[[@CR11], [@CR12]\] have suggested that bariatric surgery is safe, there is a paucity of data describing the outcomes of T2DM in these individuals or, in fact, the uptake of surgery.

Summarized clinical outcomes for our case series (*n* = 3) are presented alongside outcomes for patients with T2DM who were not HIV infected (*n* = 117) in Table [4](#Tab4){ref-type="table"}. Case 1 (AGB) achieved weight loss, which was 53% excessive weight loss (EWL) in excess of the figure typically quoted for this procedure (40%) \[[@CR13]\]. This is particularly impressive as a restrictive procedure. Cases 1 and 2 were also noted to achieve greater % EWL compared to the non-HIV group for their respective procedures. Case 3, however, achieved below average % EWL for SG (30% compared to 60% reported \[[@CR14]\]), although this was not far from the average % EWL for the non-HIV group (42% ± 20%). We speculate that several patient factors, including negative eating habits, depression, and sedentary life style, may all have contributed to this outcome.Table 4Summary of clinical outcomes in patients who are human immunodeficiency virus positive and patients who are not human immunodeficiency virus positive referred for bariatric surgeryBaseline\
BMI%TWL\
postop after 2 years%EWL\
postop after 2 yearsHbA1cComplete remission of T2DM^1^PreopPostop after 1 yearHIV case 1 (AGB)46.624.4%52.6%4133NoHIV case 2 (SG)50.725.2%49.8%3532YesHIV case 3 (SG)47.814.1%29.5%12890NoAGB-non HIV (n = 61)43.4 ± 6.214% ± 8%34% ± 22%60.6 ± 18.158.2 ± 13.55%SG-non HIV (n = 56)49.6 ± 10.722% ± 9%42% ± 20%59.5 ± 18.554.4 ± 18.127%*AGB* adjustable gastric band, *BMI* body mass index, *EWL* excessive weight loss, *HbA1c* glycated hemoglobin, *HIV* human immunodeficiency virus, *SG* sleeve gastrectomy, *T2DM* type 2 diabetes mellitus, *TWL* total weight loss. ^1^ according to American Diabetes Association criteria \[[@CR8]\]. Data in non-HIV group were described as mean ± standard deviation

In terms of T2DM, although only Case 2 achieved remission according to ADA criteria \[[@CR8]\], it is notable that all cases achieved an improvement in HbA1c postoperatively. Ongoing monitoring for relapse is advisable. Case 1 would also have achieved remission were it not for the continuation of metformin postoperatively. Although T2DM outcomes for Case 3 did not objectively seem as successful, it is notable that individual insulin requirements and pill burden were reduced. Lack of remission was perhaps predictable given the longevity of T2DM and preoperative insulin dosage.

In all three cases, HIV status was not affected by bariatric surgery, which is consistent with existing literature \[[@CR4], [@CR6], [@CR11], [@CR12], [@CR15]\]. There is a theoretical concern over drug absorption following bariatric surgery. One study to date has reported that, despite a mild reduction, drug levels following SG remained within the therapeutic range \[[@CR12]\]. In our case series, the HIV status was not adversely affected by bariatric surgery.

Conclusions {#Sec8}
===========

In conclusion, our case series further supports the use of bariatric surgery as a safe treatment modality in individuals who are HIV positive \[[@CR11]\]. Importantly, we have demonstrated the positive effect of bariatric surgery on T2DM in this group of patients. Further work would be beneficial to consolidate these findings.
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